🍂 Enjoy the Fall Season! 🍂
MindTheDesk

China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts

Global - Asia Archived • September 25, 2026 •
China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts
Chinese biotech deal making is moving beyond the licensing of individual drug candidates, as the country transforms from a follower to a global innovation leader, according to analysts.
The latest transaction underscores that shift. Beijing-based cancer drug developer InnoCare Pharma said on Thursday that it had entered into a strategic research collaboration and licensing agreement with US pharmaceutical giant Eli Lilly that could be worth up to US$3.35 billion.
InnoCare said it would use its...
Source: South China Morning Post | https://www.scmp.com/rss/91/feed - Read Original
"House Plans for Structures New and Old"

Discussion (0)

Please log in to post a comment.

No comments yet. Be the first to share your thoughts!

Sponsored
"Get your business promoted today."